Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19473768 | 0.86 | USP30 (0.51) | KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL20872894 | 0.83 | KCNJ1 (0.53) | HPGDSKMT2AKDM4EMEN1MAPT | |
| SCHEMBL19457858 | 0.79 | KCNJ1 (0.48) | KMT2AMEN1KCNJ1KCNH2ALDH1A1 | |
| SCHEMBL20985104 | 0.74 | KMT2A (0.42) | KMT2AMEN1SMYD3 | |
| SCHEMBL20944530 | 0.73 | KDM4E (0.51) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL20944532 | 0.73 | KDM4E (0.51) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL16973743 | 0.73 | PRKAA2 (0.46) | SMYD3 | |
| SCHEMBL17310021 | 0.73 | KDM4E (0.43) | KMT2AKDM4EMEN1MAPTALDH1A1 | |
| SCHEMBL29085228 | 0.73 | GPR6 (0.46) | HPGDSNPC1RAB9APDCD1CD274 | |
| SCHEMBL29085224 | 0.73 | GPR6 (0.46) | HPGDSNPC1RAB9APDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059810-B2 | Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-07-13 | — | — | US | disclosed |
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-20200123135-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-04-23 | — | — | US | disclosed |
| US-10442794-B2 | Processes for preparing pyridine carboxamide derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-10-15 | — | — | US | disclosed |
| US-10364234-B2 | Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-07-30 | — | — | US | disclosed |
| US-20190152958-A1 | PHARMACEUTICAL USES OF PYRIDINE CARBOXAMIDE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190152959-A1 | PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3466945-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-04-10 | — | — | EP | disclosed |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
| EP-3231802-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2017-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152958-A1 | PHARMACEUTICAL USES OF PYRIDINE CARBOXAMIDE DERIVATIVES | CASK, PDXK, NADK | HPGDS 2125/4885KMT2A 1897/4885KDM4E 910/4885 |
| US-20190152959-A1 | PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES | CPS1, PDXK, SDHA | HPGDS 1416/4885KMT2A 1137/4885KDM4E 358/4885 |
| US-10442794-B2 | Processes for preparing pyridine carboxamide derivatives | CPS1, PDXK, SDHA | HPGDS 1416/4885KMT2A 1137/4885KDM4E 358/4885 |
| US-20170342059-A1 | PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF | KCNK2, KCNJ2, KCNK5 | HPGDS 2605/4885KMT2A 1761/4885KDM4E 577/4885 |
| US-10364234-B2 | Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof | KCNK2, KCNJ2, KCNK5 | HPGDS 2605/4885KMT2A 1761/4885KDM4E 577/4885 |
| US-11059810-B2 | Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor | KCNK10, CASK, KCNN2 | HPGDS 4870/4885KMT2A 1177/4885KDM4E 1867/4885 |
| US-20200123135-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AS RENAL OUTER MEDULLARY POTASSIUM CHANNEL INHIBITOR | KCNK10, CASK, KCNN2 | HPGDS 4870/4885KMT2A 1177/4885KDM4E 1867/4885 |
| US-10759788-B2 | Pharmaceutical uses of pyridine carboxamide derivatives | CASK, PDXK, NADK | HPGDS 2125/4885KMT2A 1897/4885KDM4E 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.